Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kayvon Dowlatshahi"'
Autor:
Kishor K. Bhakat, Geoffrey Talmon, Vimla Band, Jing Wang, Kayvon Dowlatshahi, Sutapa Ray, Bhopal Mohapatra, Pranjal Biswas, Shrabasti Roychoudhury, Jiping Zeng, Heyu Song
Fluorouracil (5-FU) remains a first-line chemotherapeutic agent for colorectal cancer. However, a subset of colorectal cancer patients who have defective mismatch-repair (dMMR) pathway show resistance to 5-FU. Here, we demonstrate that the efficacy o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b1843bf67d130859e00938e1ddd3021
https://doi.org/10.1158/1535-7163.c.6542323
https://doi.org/10.1158/1535-7163.c.6542323
Autor:
Kishor K. Bhakat, Geoffrey Talmon, Vimla Band, Jing Wang, Kayvon Dowlatshahi, Sutapa Ray, Bhopal Mohapatra, Pranjal Biswas, Shrabasti Roychoudhury, Jiping Zeng, Heyu Song
Figure S1. IC50 decreased after APE1 knockdown. Figure S2. MMS increased colocalization of APE1 and FACT complex. Figure S3. FACT knockdown did not affect total APE1 level but decreased the occupancy of APE1 to p21 and DTL promoters. Figure S4. CBL01
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cd119a27cebb62635e8405ddebb4e70
https://doi.org/10.1158/1535-7163.22519156
https://doi.org/10.1158/1535-7163.22519156
Publikováno v:
American Journal of Gastroenterology. 115:S1485-S1486
INTRODUCTION: SARS-CoV-2 most commonly presents with respiratory symptoms and fever A significant proportion of patients are also experiencing gastrointestinal (GI) symptoms with loss of appetite, nausea, vomiting and diarrhea (variable, up to 10%);h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf1c05d6d76d5f9c41af4348acacda3c
https://doi.org/10.14309/01.ajg.0000713412.30585.4f
https://doi.org/10.14309/01.ajg.0000713412.30585.4f
Autor:
Pranjal Biswas, Bhopal Mohapatra, Shrabasti Roychoudhury, Heyu Song, Jiping Zeng, Vimla Band, Jing Wang, Geoffrey A. Talmon, Sutapa Ray, Kayvon Dowlatshahi, Kishor K. Bhakat
Publikováno v:
Mol Cancer Ther
Fluorouracil (5-FU) remains a first-line chemotherapeutic agent for colorectal cancer. However, a subset of colorectal cancer patients who have defective mismatch-repair (dMMR) pathway show resistance to 5-FU. Here, we demonstrate that the efficacy o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b0cf149b9e1e3c119de5f7f28cbe01e
https://europepmc.org/articles/PMC6946866/
https://europepmc.org/articles/PMC6946866/